Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magné N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E.

BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.

2.

Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma.

De Barros A, Attal J, Roques M, Nicolau J, Sol JC, Cohen-Jonathan-Moyal E, Roux FE.

J Neurooncol. 2019 Feb 19. doi: 10.1007/s11060-019-03120-3. [Epub ahead of print]

PMID:
30783874
3.

Molecular PET imaging in adaptive radiotherapy: brain.

Peyraga G, Robaine N, Khalifa J, Cohen-Jonathan-Moyal E, Payoux P, Laprie A.

Q J Nucl Med Mol Imaging. 2018 Dec;62(4):337-348. doi: 10.23736/S1824-4785.18.03116-3. Review.

4.

RND1 regulates migration of human glioblastoma stem-like cells according to their anatomical localization and defines a prognostic signature in glioblastoma.

Boyrie S, Delmas C, Lemarié A, Lubrano V, Dahan P, Malric L, Luis J, Gilhodes J, Tosolini M, Mouly L, Lehmann M, Toulas C, Cohen-Jonathan Moyal E, Monferran S.

Oncotarget. 2018 Sep 18;9(73):33788-33803. doi: 10.18632/oncotarget.26082. eCollection 2018 Sep 18.

5.

FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker.

Gouazé-Andersson V, Ghérardi MJ, Lemarié A, Gilhodes J, Lubrano V, Arnauduc F, Cohen-Jonathan Moyal E, Toulas C.

Oncotarget. 2018 Aug 3;9(60):31637-31649. doi: 10.18632/oncotarget.25827. eCollection 2018 Aug 3.

6.

Alpha-6 integrin promotes radioresistance of glioblastoma by modulating DNA damage response and the transcription factor Zeb1.

Kowalski-Chauvel A, Modesto A, Gouaze-Andersson V, Baricault L, Gilhodes J, Delmas C, Lemarie A, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Cell Death Dis. 2018 Aug 29;9(9):872. doi: 10.1038/s41419-018-0853-x.

7.

Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.

Attal J, Chaltiel L, Lubrano V, Sol JC, Lanaspeze C, Vieillevigne L, Latorzeff I, Cohen-Jonathan Moyal E.

J Neurooncol. 2018 Jan;136(2):413-419. doi: 10.1007/s11060-017-2669-4. Epub 2017 Dec 22.

PMID:
29273890
8.

By modulating α2β1 integrin signalling, gastrin increases adhesion oF AGS-GR gastric cancer cells.

Kowalski-Chauvel A, Teissier G, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Exp Cell Res. 2018 Jan 15;362(2):498-503. doi: 10.1016/j.yexcr.2017.12.014. Epub 2017 Dec 15.

PMID:
29253536
9.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
10.

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A.

Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Review.

11.

Oral lesions of acute generalized exanthematous pustulosis.

Vigarios E, Tournier E, Pouessel D, Cohen-Jonathan-Moyal E, Sibaud V.

Int J Dermatol. 2017 Dec;56(12):1465-1467. doi: 10.1111/ijd.13754. Epub 2017 Sep 27. No abstract available.

PMID:
28952158
12.

Targeting progastrin enhances radiosensitization of colorectal cancer cells.

Kowalski-Chauvel A, Gouaze-Andersson V, Vignolle-Vidoni A, Delmas C, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Oncotarget. 2017 Apr 20;8(35):58587-58600. doi: 10.18632/oncotarget.17274. eCollection 2017 Aug 29.

13.

Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.

Tensaouti F, Khalifa J, Lusque A, Plas B, Lotterie JA, Berry I, Laprie A, Cohen-Jonathan Moyal E, Lubrano V.

Neuroradiology. 2017 Oct;59(10):1013-1020. doi: 10.1007/s00234-017-1899-7. Epub 2017 Aug 25.

PMID:
28842741
14.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

15.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

16.

Subventricular zones: new key targets for glioblastoma treatment.

Khalifa J, Tensaouti F, Lusque A, Plas B, Lotterie JA, Benouaich-Amiel A, Uro-Coste E, Lubrano V, Cohen-Jonathan Moyal E.

Radiat Oncol. 2017 Apr 20;12(1):67. doi: 10.1186/s13014-017-0791-2.

17.

Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?

Khalifa J, Tensaouti F, Lotterie JA, Catalaa I, Chaltiel L, Benouaich-Amiel A, Gomez-Roca C, Noël G, Truc G, Péran P, Berry I, Sunyach MP, Charissoux M, Johnson C, Cohen-Jonathan Moyal E, Laprie A.

J Neurooncol. 2016 Oct;130(1):181-192. Epub 2016 Aug 8.

PMID:
27502603
18.

FGFR1 Induces Glioblastoma Radioresistance through the PLCγ/Hif1α Pathway.

Gouazé-Andersson V, Delmas C, Taurand M, Martinez-Gala J, Evrard S, Mazoyer S, Toulas C, Cohen-Jonathan-Moyal E.

Cancer Res. 2016 May 15;76(10):3036-44. doi: 10.1158/0008-5472.CAN-15-2058. Epub 2016 Feb 19.

19.

Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Cohen-Jonathan Moyal E, Sarry JE, Skuli N.

PLoS One. 2015 Apr 13;10(4):e0123721. doi: 10.1371/journal.pone.0123721. eCollection 2015.

20.

Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.

Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, Lubrano V, Toulas C, Cohen-Jonathan Moyal E, Lemarie A.

Cell Death Dis. 2014 Nov 27;5:e1543. doi: 10.1038/cddis.2014.509.

21.

Progastrin a new pro-angiogenic factor in colorectal cancer.

Najib S, Kowalski-Chauvel A, Do C, Roche S, Cohen-Jonathan-Moyal E, Seva C.

Oncogene. 2015 Jun 11;34(24):3120-30. doi: 10.1038/onc.2014.255. Epub 2014 Aug 11.

PMID:
25109333
22.

Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.

Deviers A, Ken S, Filleron T, Rowland B, Laruelo A, Catalaa I, Lubrano V, Celsis P, Berry I, Mogicato G, Cohen-Jonathan Moyal E, Laprie A.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):385-93. doi: 10.1016/j.ijrobp.2014.06.009. Epub 2014 Aug 4.

PMID:
25104068
23.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma.

Lancet Oncol. 2014 Aug;15(9):e395-403. doi: 10.1016/S1470-2045(14)70011-7. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

24.

Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.

Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E, Toulas C.

Eur J Cancer. 2014 Sep;50(13):2351-9. doi: 10.1016/j.ejca.2014.05.012. Epub 2014 Jun 18.

PMID:
24953334
25.

Activation of pro-oncogenic pathways in colorectal hyperplastic polyps.

Do C, Bertrand C, Palasse J, Delisle MB, Cohen-Jonathan-Moyal E, Seva C.

BMC Cancer. 2013 Nov 8;13:531. doi: 10.1186/1471-2407-13-531.

26.

Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells.

Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E.

Eur J Cancer. 2013 Sep;49(13):2884-91. doi: 10.1016/j.ejca.2013.05.003. Epub 2013 Jun 6.

PMID:
23747271
27.

αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.

Ducassou A, Uro-Coste E, Verrelle P, Filleron T, Benouaich-Amiel A, Lubrano V, Sol JC, Delisle MB, Favre G, Ken S, Laprie A, De Porre P, Toulas C, Poublanc M, Cohen-Jonathan Moyal E.

Eur J Cancer. 2013 Jun;49(9):2161-9. doi: 10.1016/j.ejca.2013.02.033. Epub 2013 Apr 6.

PMID:
23566417
28.

Identification of the F1-ATPase at the cell surface of colonic epithelial cells: role in mediating cell proliferation.

Kowalski-Chauvel A, Najib S, Tikhonova IG, Huc L, Lopez F, Martinez LO, Cohen-Jonathan-Moyal E, Ferrand A, Seva C.

J Biol Chem. 2012 Nov 30;287(49):41458-68. doi: 10.1074/jbc.M112.382465. Epub 2012 Oct 10.

29.

The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?

Massabeau C, Sigal-Zafrani B, Belin L, Savignoni A, Richardson M, Kirova YM, Cohen-Jonathan-Moyal E, Mégnin-Chanet F, Hall J, Fourquet A.

Breast Cancer Res Treat. 2012 Jul;134(1):259-66. doi: 10.1007/s10549-012-2027-3. Epub 2012 Mar 22.

PMID:
22438050
30.

A new biomarker that predicts colonic neoplasia outcome in patients with hyperplastic colonic polyps.

Do C, Bertrand C, Palasse J, Delisle MB, Shulkes A, Cohen-Jonathan-Moyal E, Ferrand A, Seva C.

Cancer Prev Res (Phila). 2012 Apr;5(4):675-84. doi: 10.1158/1940-6207.CAPR-11-0408. Epub 2012 Feb 24.

31.

[From bench to bedside: experience of the glioblastoma model for the optimization of radiosensitization].

Cohen-Jonathan Moyal E.

Cancer Radiother. 2012 Feb;16(1):25-8. doi: 10.1016/j.canrad.2011.10.007. Epub 2012 Feb 1. Review. French.

PMID:
22301061
32.

αv integrin: a new gastrin target in human pancreatic cancer cells.

Cayrol C, Bertrand C, Kowalski-Chauvel A, Daulhac L, Cohen-Jonathan-Moyal E, Ferrand A, Seva C.

World J Gastroenterol. 2011 Oct 28;17(40):4488-95. doi: 10.3748/wjg.v17.i40.4488.

33.

The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.

Massabeau C, Filleron T, Wakil G, Rouquette I, Bachaud JM, Leguellec S, Delisle MB, Toulas C, Mazieres J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2012 Jan;13(1):59-67. doi: 10.1016/j.cllc.2011.06.011.

PMID:
21856239
34.

[Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].

Cohen-Jonathan Moyal E.

Cancer Radiother. 2009 Oct;13(6-7):562-7. doi: 10.1016/j.canrad.2009.07.007. Epub 2009 Aug 19. Review. French.

PMID:
19695923
35.

Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.

Massabeau C, Rouquette I, Lauwers-Cances V, Mazières J, Bachaud JM, Armand JP, Delisle MB, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):696-702. doi: 10.1016/j.ijrobp.2008.11.050. Epub 2009 Apr 20.

PMID:
19386436
36.

Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.

Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E.

Cancer Res. 2009 Apr 15;69(8):3308-16. doi: 10.1158/0008-5472.CAN-08-2158. Epub 2009 Apr 7.

37.

Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.

Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E, Toulas C.

Int J Cancer. 2008 Jul 15;123(2):357-364. doi: 10.1002/ijc.23498.

38.

Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.

Skuli N, Monferran S, Delmas C, Lajoie-Mazenc I, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Cancer Res. 2006 Jan 1;66(1):482-9.

39.

Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts.

Ader I, Delmas C, Bonnet J, Rochaix P, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Oncogene. 2003 Dec 4;22(55):8861-9.

PMID:
14654782

Supplemental Content

Loading ...
Support Center